Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.37 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.33 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1I known ✓ | Q9P0X4 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29612153 | 1.00 | CYP11B1 (0.44) | CYP11B1GRM2PARP1TRPV6CYP19A1 | |
| SCHEMBL502659 | 0.98 | — | — | |
| SCHEMBL10484015 | 0.78 | CYP11B1 (0.42) | CYP11B1GRM2PARP1TRPV6 | |
| SCHEMBL10483902 | 0.77 | CYP11B1 (0.41) | CYP11B1GRM2PARP1TRPV6 | |
| SCHEMBL485115 | 0.76 | — | — | |
| SCHEMBL29725206 | 0.76 | — | — | |
| SCHEMBL1274691 | 0.74 | — | — | |
| SCHEMBL2180629 | 0.74 | — | — | |
| SCHEMBL1193384 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL7501190 | 0.74 | GAA (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3016946-B1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-108440515-B | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | 卡尔约药物治疗公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | disclosed |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-04-02 | — | — | US | disclosed |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2018-11-08 | — | — | US | disclosed |
| CN-108440515-A | Substituted benzofuranyl and benzoxazole based compound and application thereof | 卡尔约药物治疗公司 | 2018-08-24 | — | — | CN | disclosed |
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-3016946-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015003166-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2015-01-08 | — | — | WO | disclosed |
| CN-101842357-A | Substituted pyrazole derivatives | TAKEDA PHARMACEUTICAL | 2010-09-22 | — | — | CN | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | PARP1 3146/4885CYP19A1 940/4885KCNH2 115/4885 |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PARP1 890/4885CYP19A1 202/4885KCNH2 2131/4885 |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | PARP1 2333/4885CYP19A1 12/4885KCNH2 1162/4885 |
| US-20180319779-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PARP1 976/4885CYP19A1 178/4885KCNH2 2102/4885 |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PARP1 976/4885CYP19A1 178/4885KCNH2 2102/4885 |
| US-11008309-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PARP1 976/4885CYP19A1 178/4885KCNH2 2102/4885 |
| US-10399963-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PARP1 976/4885CYP19A1 178/4885KCNH2 2102/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | PARP1 2314/4885CYP19A1 12/4885KCNH2 1107/4885 |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PARP1 976/4885CYP19A1 178/4885KCNH2 2102/4885 |
| US-20200102292-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PARP1 976/4885CYP19A1 178/4885KCNH2 2102/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | PARP1 1996/4885CYP19A1 426/4885KCNH2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.